Seeking Alpha

Oxigene (OXGN +17.5%) pops after saying its randomized Phase 2 study evaluating the combination...

Oxigene (OXGN +17.5%) pops after saying its randomized Phase 2 study evaluating the combination of zybrestat and bevacizumab to treat patients with advanced ovarian cancer achieved important safety objectives in a scheduled interim toxicity analysis, and it's expected to continue to full enrollment.
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs